Global Recombinant Human Coagulation Factor IX Market Growth 2026-2032
The global Recombinant Human Coagulation Factor IX market size is predicted to grow from US$ 574 million in 2025 to US$ 739 million in 2032; it is expected to grow at a CAGR of 3.7% from 2026 to 2032.
Recombinant human coagulation factor IX is a drug produced by genetic recombination technology, mainly used to treat hemophilia B (i.e. congenital coagulation factor IX deficiency). Its function is to supplement the coagulation factor IX that is lacking in the patient's body to help control and prevent bleeding. The drug is a colorless and clear solution after reconstitution. It is suitable for daily bleeding management and perioperative management of hemophilia B patients, but is not suitable for the treatment of other types of coagulation factor deficiency or conditions related to the anticoagulant effect of coumarin.
United States market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Recombinant Human Coagulation Factor IX players cover Grifols, Biogen, Octapharma, Baxter, Cusabio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Coagulation Factor IX landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Coagulation Factor IX portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human Coagulation Factor IX market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Coagulation Factor IX and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Coagulation Factor IX.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Coagulation Factor IX market by product type, application, key manufacturers and key regions and countries.
Recombinant human coagulation factor IX is a drug produced by genetic recombination technology, mainly used to treat hemophilia B (i.e. congenital coagulation factor IX deficiency). Its function is to supplement the coagulation factor IX that is lacking in the patient's body to help control and prevent bleeding. The drug is a colorless and clear solution after reconstitution. It is suitable for daily bleeding management and perioperative management of hemophilia B patients, but is not suitable for the treatment of other types of coagulation factor deficiency or conditions related to the anticoagulant effect of coumarin.
United States market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Recombinant Human Coagulation Factor IX players cover Grifols, Biogen, Octapharma, Baxter, Cusabio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Human Coagulation Factor IX Industry Forecast” looks at past sales and reviews total world Recombinant Human Coagulation Factor IX sales in 2025, providing a comprehensive analysis by region and market sector of projected Recombinant Human Coagulation Factor IX sales for 2026 through 2032. With Recombinant Human Coagulation Factor IX sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Coagulation Factor IX industry.This Insight Report provides a comprehensive analysis of the global Recombinant Human Coagulation Factor IX landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Coagulation Factor IX portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human Coagulation Factor IX market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Coagulation Factor IX and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Coagulation Factor IX.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Coagulation Factor IX market by product type, application, key manufacturers and key regions and countries.
Market Segmentation
Segmentation by Type:
- 250 IU/Bottle
- 500 IU/Bottle
- 1000 IU/Bottle
- 2000 IU/Bottle
Segmentation by Application:
- Adult Patients
- Child Patients
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Grifols
- Biogen
- Octapharma
- Baxter
- Cusabio
- Sanofi
- Cayman
- NovoPro Bioscience
- Sino Biological
- Bio-Techne
- IDELVION
- Hualan Bio
- Shuyang
- ChinaBiologic
- Diagbio
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Recombinant Human Coagulation Factor IX market?
- What factors are driving Recombinant Human Coagulation Factor IX market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Recombinant Human Coagulation Factor IX market opportunities vary by end market size?
- How does Recombinant Human Coagulation Factor IX break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Recombinant Human Coagulation Factor IX by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Recombinant Human Coagulation Factor IX by Country/Region, 2021, 2025 & 2032
2.2 Recombinant Human Coagulation Factor IX Segment by Type
2.2.1 250 IU/Bottle
2.2.2 500 IU/Bottle
2.2.3 1000 IU/Bottle
2.2.4 2000 IU/Bottle
2.2.5 Recombinant Human Coagulation Factor IX Sales by Type
2.2.5.1 Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
2.2.5.2 Global Recombinant Human Coagulation Factor IX Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Recombinant Human Coagulation Factor IX Sale Price by Type (2021-2026)
2.3 Recombinant Human Coagulation Factor IX Segment by Application
2.3.1 Adult Patients
2.3.2 Child Patients
2.3.3 Recombinant Human Coagulation Factor IX Sales by Application
2.3.3.1 Global Recombinant Human Coagulation Factor IX Sale Market Share by Application (2021-2026)
2.3.3.2 Global Recombinant Human Coagulation Factor IX Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Recombinant Human Coagulation Factor IX Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Recombinant Human Coagulation Factor IX Breakdown Data by Company
3.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Company (2021-2026)
3.1.2 Global Recombinant Human Coagulation Factor IX Sales Market Share by Company (2021-2026)
3.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Company (2021-2026)
3.2.1 Global Recombinant Human Coagulation Factor IX Revenue by Company (2021-2026)
3.2.2 Global Recombinant Human Coagulation Factor IX Revenue Market Share by Company (2021-2026)
3.3 Global Recombinant Human Coagulation Factor IX Sale Price by Company
3.4 Key Manufacturers Recombinant Human Coagulation Factor IX Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human Coagulation Factor IX Product Location Distribution
3.4.2 Players Recombinant Human Coagulation Factor IX Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN COAGULATION FACTOR IX BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Human Coagulation Factor IX Market Size by Geographic Region (2021-2026)
4.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Recombinant Human Coagulation Factor IX Market Size by Country/Region (2021-2026)
4.2.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Country/Region (2021-2026)
4.2.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Country/Region (2021-2026)
4.3 Americas Recombinant Human Coagulation Factor IX Sales Growth
4.4 APAC Recombinant Human Coagulation Factor IX Sales Growth
4.5 Europe Recombinant Human Coagulation Factor IX Sales Growth
4.6 Middle East & Africa Recombinant Human Coagulation Factor IX Sales Growth
5 AMERICAS
5.1 Americas Recombinant Human Coagulation Factor IX Sales by Country
5.1.1 Americas Recombinant Human Coagulation Factor IX Sales by Country (2021-2026)
5.1.2 Americas Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026)
5.2 Americas Recombinant Human Coagulation Factor IX Sales by Type (2021-2026)
5.3 Americas Recombinant Human Coagulation Factor IX Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Coagulation Factor IX Sales by Region
6.1.1 APAC Recombinant Human Coagulation Factor IX Sales by Region (2021-2026)
6.1.2 APAC Recombinant Human Coagulation Factor IX Revenue by Region (2021-2026)
6.2 APAC Recombinant Human Coagulation Factor IX Sales by Type (2021-2026)
6.3 APAC Recombinant Human Coagulation Factor IX Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Human Coagulation Factor IX by Country
7.1.1 Europe Recombinant Human Coagulation Factor IX Sales by Country (2021-2026)
7.1.2 Europe Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026)
7.2 Europe Recombinant Human Coagulation Factor IX Sales by Type (2021-2026)
7.3 Europe Recombinant Human Coagulation Factor IX Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Human Coagulation Factor IX by Country
8.1.1 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Country (2021-2026)
8.1.2 Middle East & Africa Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026)
8.2 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Type (2021-2026)
8.3 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Coagulation Factor IX
10.3 Manufacturing Process Analysis of Recombinant Human Coagulation Factor IX
10.4 Industry Chain Structure of Recombinant Human Coagulation Factor IX
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human Coagulation Factor IX Distributors
11.3 Recombinant Human Coagulation Factor IX Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN COAGULATION FACTOR IX BY GEOGRAPHIC REGION
12.1 Global Recombinant Human Coagulation Factor IX Market Size Forecast by Region
12.1.1 Global Recombinant Human Coagulation Factor IX Forecast by Region (2027-2032)
12.1.2 Global Recombinant Human Coagulation Factor IX Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Recombinant Human Coagulation Factor IX Forecast by Type (2027-2032)
12.7 Global Recombinant Human Coagulation Factor IX Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Grifols
13.1.1 Grifols Company Information
13.1.2 Grifols Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.1.3 Grifols Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Grifols Main Business Overview
13.1.5 Grifols Latest Developments
13.2 Biogen
13.2.1 Biogen Company Information
13.2.2 Biogen Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.2.3 Biogen Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Biogen Main Business Overview
13.2.5 Biogen Latest Developments
13.3 Octapharma
13.3.1 Octapharma Company Information
13.3.2 Octapharma Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.3.3 Octapharma Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Octapharma Main Business Overview
13.3.5 Octapharma Latest Developments
13.4 Baxter
13.4.1 Baxter Company Information
13.4.2 Baxter Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.4.3 Baxter Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Baxter Main Business Overview
13.4.5 Baxter Latest Developments
13.5 Cusabio
13.5.1 Cusabio Company Information
13.5.2 Cusabio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.5.3 Cusabio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Cusabio Main Business Overview
13.5.5 Cusabio Latest Developments
13.6 Sanofi
13.6.1 Sanofi Company Information
13.6.2 Sanofi Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.6.3 Sanofi Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Sanofi Main Business Overview
13.6.5 Sanofi Latest Developments
13.7 Cayman
13.7.1 Cayman Company Information
13.7.2 Cayman Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.7.3 Cayman Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Cayman Main Business Overview
13.7.5 Cayman Latest Developments
13.8 NovoPro Bioscience
13.8.1 NovoPro Bioscience Company Information
13.8.2 NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.8.3 NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 NovoPro Bioscience Main Business Overview
13.8.5 NovoPro Bioscience Latest Developments
13.9 Sino Biological
13.9.1 Sino Biological Company Information
13.9.2 Sino Biological Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.9.3 Sino Biological Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Sino Biological Main Business Overview
13.9.5 Sino Biological Latest Developments
13.10 Bio-Techne
13.10.1 Bio-Techne Company Information
13.10.2 Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.10.3 Bio-Techne Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Bio-Techne Main Business Overview
13.10.5 Bio-Techne Latest Developments
13.11 IDELVION
13.11.1 IDELVION Company Information
13.11.2 IDELVION Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.11.3 IDELVION Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 IDELVION Main Business Overview
13.11.5 IDELVION Latest Developments
13.12 Hualan Bio
13.12.1 Hualan Bio Company Information
13.12.2 Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.12.3 Hualan Bio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Hualan Bio Main Business Overview
13.12.5 Hualan Bio Latest Developments
13.13 Shuyang
13.13.1 Shuyang Company Information
13.13.2 Shuyang Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.13.3 Shuyang Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Shuyang Main Business Overview
13.13.5 Shuyang Latest Developments
13.14 ChinaBiologic
13.14.1 ChinaBiologic Company Information
13.14.2 ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.14.3 ChinaBiologic Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 ChinaBiologic Main Business Overview
13.14.5 ChinaBiologic Latest Developments
13.15 Diagbio
13.15.1 Diagbio Company Information
13.15.2 Diagbio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.15.3 Diagbio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Diagbio Main Business Overview
13.15.5 Diagbio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Recombinant Human Coagulation Factor IX by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Recombinant Human Coagulation Factor IX by Country/Region, 2021, 2025 & 2032
2.2 Recombinant Human Coagulation Factor IX Segment by Type
2.2.1 250 IU/Bottle
2.2.2 500 IU/Bottle
2.2.3 1000 IU/Bottle
2.2.4 2000 IU/Bottle
2.2.5 Recombinant Human Coagulation Factor IX Sales by Type
2.2.5.1 Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
2.2.5.2 Global Recombinant Human Coagulation Factor IX Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Recombinant Human Coagulation Factor IX Sale Price by Type (2021-2026)
2.3 Recombinant Human Coagulation Factor IX Segment by Application
2.3.1 Adult Patients
2.3.2 Child Patients
2.3.3 Recombinant Human Coagulation Factor IX Sales by Application
2.3.3.1 Global Recombinant Human Coagulation Factor IX Sale Market Share by Application (2021-2026)
2.3.3.2 Global Recombinant Human Coagulation Factor IX Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Recombinant Human Coagulation Factor IX Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Recombinant Human Coagulation Factor IX Breakdown Data by Company
3.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Company (2021-2026)
3.1.2 Global Recombinant Human Coagulation Factor IX Sales Market Share by Company (2021-2026)
3.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Company (2021-2026)
3.2.1 Global Recombinant Human Coagulation Factor IX Revenue by Company (2021-2026)
3.2.2 Global Recombinant Human Coagulation Factor IX Revenue Market Share by Company (2021-2026)
3.3 Global Recombinant Human Coagulation Factor IX Sale Price by Company
3.4 Key Manufacturers Recombinant Human Coagulation Factor IX Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human Coagulation Factor IX Product Location Distribution
3.4.2 Players Recombinant Human Coagulation Factor IX Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN COAGULATION FACTOR IX BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Human Coagulation Factor IX Market Size by Geographic Region (2021-2026)
4.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Recombinant Human Coagulation Factor IX Market Size by Country/Region (2021-2026)
4.2.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Country/Region (2021-2026)
4.2.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Country/Region (2021-2026)
4.3 Americas Recombinant Human Coagulation Factor IX Sales Growth
4.4 APAC Recombinant Human Coagulation Factor IX Sales Growth
4.5 Europe Recombinant Human Coagulation Factor IX Sales Growth
4.6 Middle East & Africa Recombinant Human Coagulation Factor IX Sales Growth
5 AMERICAS
5.1 Americas Recombinant Human Coagulation Factor IX Sales by Country
5.1.1 Americas Recombinant Human Coagulation Factor IX Sales by Country (2021-2026)
5.1.2 Americas Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026)
5.2 Americas Recombinant Human Coagulation Factor IX Sales by Type (2021-2026)
5.3 Americas Recombinant Human Coagulation Factor IX Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Coagulation Factor IX Sales by Region
6.1.1 APAC Recombinant Human Coagulation Factor IX Sales by Region (2021-2026)
6.1.2 APAC Recombinant Human Coagulation Factor IX Revenue by Region (2021-2026)
6.2 APAC Recombinant Human Coagulation Factor IX Sales by Type (2021-2026)
6.3 APAC Recombinant Human Coagulation Factor IX Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Human Coagulation Factor IX by Country
7.1.1 Europe Recombinant Human Coagulation Factor IX Sales by Country (2021-2026)
7.1.2 Europe Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026)
7.2 Europe Recombinant Human Coagulation Factor IX Sales by Type (2021-2026)
7.3 Europe Recombinant Human Coagulation Factor IX Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Human Coagulation Factor IX by Country
8.1.1 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Country (2021-2026)
8.1.2 Middle East & Africa Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026)
8.2 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Type (2021-2026)
8.3 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Coagulation Factor IX
10.3 Manufacturing Process Analysis of Recombinant Human Coagulation Factor IX
10.4 Industry Chain Structure of Recombinant Human Coagulation Factor IX
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human Coagulation Factor IX Distributors
11.3 Recombinant Human Coagulation Factor IX Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN COAGULATION FACTOR IX BY GEOGRAPHIC REGION
12.1 Global Recombinant Human Coagulation Factor IX Market Size Forecast by Region
12.1.1 Global Recombinant Human Coagulation Factor IX Forecast by Region (2027-2032)
12.1.2 Global Recombinant Human Coagulation Factor IX Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Recombinant Human Coagulation Factor IX Forecast by Type (2027-2032)
12.7 Global Recombinant Human Coagulation Factor IX Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Grifols
13.1.1 Grifols Company Information
13.1.2 Grifols Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.1.3 Grifols Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Grifols Main Business Overview
13.1.5 Grifols Latest Developments
13.2 Biogen
13.2.1 Biogen Company Information
13.2.2 Biogen Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.2.3 Biogen Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Biogen Main Business Overview
13.2.5 Biogen Latest Developments
13.3 Octapharma
13.3.1 Octapharma Company Information
13.3.2 Octapharma Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.3.3 Octapharma Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Octapharma Main Business Overview
13.3.5 Octapharma Latest Developments
13.4 Baxter
13.4.1 Baxter Company Information
13.4.2 Baxter Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.4.3 Baxter Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Baxter Main Business Overview
13.4.5 Baxter Latest Developments
13.5 Cusabio
13.5.1 Cusabio Company Information
13.5.2 Cusabio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.5.3 Cusabio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Cusabio Main Business Overview
13.5.5 Cusabio Latest Developments
13.6 Sanofi
13.6.1 Sanofi Company Information
13.6.2 Sanofi Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.6.3 Sanofi Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Sanofi Main Business Overview
13.6.5 Sanofi Latest Developments
13.7 Cayman
13.7.1 Cayman Company Information
13.7.2 Cayman Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.7.3 Cayman Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Cayman Main Business Overview
13.7.5 Cayman Latest Developments
13.8 NovoPro Bioscience
13.8.1 NovoPro Bioscience Company Information
13.8.2 NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.8.3 NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 NovoPro Bioscience Main Business Overview
13.8.5 NovoPro Bioscience Latest Developments
13.9 Sino Biological
13.9.1 Sino Biological Company Information
13.9.2 Sino Biological Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.9.3 Sino Biological Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Sino Biological Main Business Overview
13.9.5 Sino Biological Latest Developments
13.10 Bio-Techne
13.10.1 Bio-Techne Company Information
13.10.2 Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.10.3 Bio-Techne Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Bio-Techne Main Business Overview
13.10.5 Bio-Techne Latest Developments
13.11 IDELVION
13.11.1 IDELVION Company Information
13.11.2 IDELVION Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.11.3 IDELVION Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 IDELVION Main Business Overview
13.11.5 IDELVION Latest Developments
13.12 Hualan Bio
13.12.1 Hualan Bio Company Information
13.12.2 Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.12.3 Hualan Bio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Hualan Bio Main Business Overview
13.12.5 Hualan Bio Latest Developments
13.13 Shuyang
13.13.1 Shuyang Company Information
13.13.2 Shuyang Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.13.3 Shuyang Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Shuyang Main Business Overview
13.13.5 Shuyang Latest Developments
13.14 ChinaBiologic
13.14.1 ChinaBiologic Company Information
13.14.2 ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.14.3 ChinaBiologic Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 ChinaBiologic Main Business Overview
13.14.5 ChinaBiologic Latest Developments
13.15 Diagbio
13.15.1 Diagbio Company Information
13.15.2 Diagbio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.15.3 Diagbio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Diagbio Main Business Overview
13.15.5 Diagbio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Recombinant Human Coagulation Factor IX Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Recombinant Human Coagulation Factor IX Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 250 IU/Bottle
Table 4. Major Players of 500 IU/Bottle
Table 5. Major Players of 1000 IU/Bottle
Table 6. Major Players of 2000 IU/Bottle
Table 7. Global Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 8. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Table 9. Global Recombinant Human Coagulation Factor IX Revenue by Type (2021-2026) & ($ million)
Table 10. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2026)
Table 11. Global Recombinant Human Coagulation Factor IX Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Global Recombinant Human Coagulation Factor IX Sale by Application (2021-2026) & (K Dose)
Table 13. Global Recombinant Human Coagulation Factor IX Sale Market Share by Application (2021-2026)
Table 14. Global Recombinant Human Coagulation Factor IX Revenue by Application (2021-2026) & ($ million)
Table 15. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2021-2026)
Table 16. Global Recombinant Human Coagulation Factor IX Sale Price by Application (2021-2026) & (US$/Dose)
Table 17. Global Recombinant Human Coagulation Factor IX Sales by Company (2021-2026) & (K Dose)
Table 18. Global Recombinant Human Coagulation Factor IX Sales Market Share by Company (2021-2026)
Table 19. Global Recombinant Human Coagulation Factor IX Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Company (2021-2026)
Table 21. Global Recombinant Human Coagulation Factor IX Sale Price by Company (2021-2026) & (US$/Dose)
Table 22. Key Manufacturers Recombinant Human Coagulation Factor IX Producing Area Distribution and Sales Area
Table 23. Players Recombinant Human Coagulation Factor IX Products Offered
Table 24. Recombinant Human Coagulation Factor IX Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Recombinant Human Coagulation Factor IX Sales by Geographic Region (2021-2026) & (K Dose)
Table 28. Global Recombinant Human Coagulation Factor IX Sales Market Share Geographic Region (2021-2026)
Table 29. Global Recombinant Human Coagulation Factor IX Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Recombinant Human Coagulation Factor IX Sales by Country/Region (2021-2026) & (K Dose)
Table 32. Global Recombinant Human Coagulation Factor IX Sales Market Share by Country/Region (2021-2026)
Table 33. Global Recombinant Human Coagulation Factor IX Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (K Dose)
Table 36. Americas Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2026)
Table 37. Americas Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 39. Americas Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (K Dose)
Table 40. APAC Recombinant Human Coagulation Factor IX Sales by Region (2021-2026) & (K Dose)
Table 41. APAC Recombinant Human Coagulation Factor IX Sales Market Share by Region (2021-2026)
Table 42. APAC Recombinant Human Coagulation Factor IX Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 44. APAC Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (K Dose)
Table 45. Europe Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (K Dose)
Table 46. Europe Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 48. Europe Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (K Dose)
Table 49. Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (K Dose)
Table 50. Middle East & Africa Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 52. Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (K Dose)
Table 53. Key Market Drivers & Growth Opportunities of Recombinant Human Coagulation Factor IX
Table 54. Key Market Challenges & Risks of Recombinant Human Coagulation Factor IX
Table 55. Key Industry Trends of Recombinant Human Coagulation Factor IX
Table 56. Recombinant Human Coagulation Factor IX Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Recombinant Human Coagulation Factor IX Distributors List
Table 59. Recombinant Human Coagulation Factor IX Customer List
Table 60. Global Recombinant Human Coagulation Factor IX Sales Forecast by Region (2027-2032) & (K Dose)
Table 61. Global Recombinant Human Coagulation Factor IX Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Recombinant Human Coagulation Factor IX Sales Forecast by Country (2027-2032) & (K Dose)
Table 63. Americas Recombinant Human Coagulation Factor IX Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Recombinant Human Coagulation Factor IX Sales Forecast by Region (2027-2032) & (K Dose)
Table 65. APAC Recombinant Human Coagulation Factor IX Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Recombinant Human Coagulation Factor IX Sales Forecast by Country (2027-2032) & (K Dose)
Table 67. Europe Recombinant Human Coagulation Factor IX Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Forecast by Country (2027-2032) & (K Dose)
Table 69. Middle East & Africa Recombinant Human Coagulation Factor IX Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Recombinant Human Coagulation Factor IX Sales Forecast by Type (2027-2032) & (K Dose)
Table 71. Global Recombinant Human Coagulation Factor IX Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Recombinant Human Coagulation Factor IX Sales Forecast by Application (2027-2032) & (K Dose)
Table 73. Global Recombinant Human Coagulation Factor IX Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Grifols Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 75. Grifols Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 76. Grifols Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 77. Grifols Main Business
Table 78. Grifols Latest Developments
Table 79. Biogen Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 80. Biogen Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 81. Biogen Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 82. Biogen Main Business
Table 83. Biogen Latest Developments
Table 84. Octapharma Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 85. Octapharma Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 86. Octapharma Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 87. Octapharma Main Business
Table 88. Octapharma Latest Developments
Table 89. Baxter Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 90. Baxter Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 91. Baxter Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Baxter Main Business
Table 93. Baxter Latest Developments
Table 94. Cusabio Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 95. Cusabio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 96. Cusabio Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Cusabio Main Business
Table 98. Cusabio Latest Developments
Table 99. Sanofi Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 100. Sanofi Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 101. Sanofi Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Sanofi Main Business
Table 103. Sanofi Latest Developments
Table 104. Cayman Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 105. Cayman Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 106. Cayman Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Cayman Main Business
Table 108. Cayman Latest Developments
Table 109. NovoPro Bioscience Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 110. NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 111. NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. NovoPro Bioscience Main Business
Table 113. NovoPro Bioscience Latest Developments
Table 114. Sino Biological Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 115. Sino Biological Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 116. Sino Biological Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Sino Biological Main Business
Table 118. Sino Biological Latest Developments
Table 119. Bio-Techne Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 120. Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 121. Bio-Techne Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Bio-Techne Main Business
Table 123. Bio-Techne Latest Developments
Table 124. IDELVION Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 125. IDELVION Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 126. IDELVION Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. IDELVION Main Business
Table 128. IDELVION Latest Developments
Table 129. Hualan Bio Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 130. Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 131. Hualan Bio Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Hualan Bio Main Business
Table 133. Hualan Bio Latest Developments
Table 134. Shuyang Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 135. Shuyang Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 136. Shuyang Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Shuyang Main Business
Table 138. Shuyang Latest Developments
Table 139. ChinaBiologic Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 140. ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 141. ChinaBiologic Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. ChinaBiologic Main Business
Table 143. ChinaBiologic Latest Developments
Table 144. Diagbio Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 145. Diagbio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 146. Diagbio Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Diagbio Main Business
Table 148. Diagbio Latest Developments
Table 1. Recombinant Human Coagulation Factor IX Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Recombinant Human Coagulation Factor IX Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 250 IU/Bottle
Table 4. Major Players of 500 IU/Bottle
Table 5. Major Players of 1000 IU/Bottle
Table 6. Major Players of 2000 IU/Bottle
Table 7. Global Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 8. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Table 9. Global Recombinant Human Coagulation Factor IX Revenue by Type (2021-2026) & ($ million)
Table 10. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2026)
Table 11. Global Recombinant Human Coagulation Factor IX Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Global Recombinant Human Coagulation Factor IX Sale by Application (2021-2026) & (K Dose)
Table 13. Global Recombinant Human Coagulation Factor IX Sale Market Share by Application (2021-2026)
Table 14. Global Recombinant Human Coagulation Factor IX Revenue by Application (2021-2026) & ($ million)
Table 15. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2021-2026)
Table 16. Global Recombinant Human Coagulation Factor IX Sale Price by Application (2021-2026) & (US$/Dose)
Table 17. Global Recombinant Human Coagulation Factor IX Sales by Company (2021-2026) & (K Dose)
Table 18. Global Recombinant Human Coagulation Factor IX Sales Market Share by Company (2021-2026)
Table 19. Global Recombinant Human Coagulation Factor IX Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Company (2021-2026)
Table 21. Global Recombinant Human Coagulation Factor IX Sale Price by Company (2021-2026) & (US$/Dose)
Table 22. Key Manufacturers Recombinant Human Coagulation Factor IX Producing Area Distribution and Sales Area
Table 23. Players Recombinant Human Coagulation Factor IX Products Offered
Table 24. Recombinant Human Coagulation Factor IX Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Recombinant Human Coagulation Factor IX Sales by Geographic Region (2021-2026) & (K Dose)
Table 28. Global Recombinant Human Coagulation Factor IX Sales Market Share Geographic Region (2021-2026)
Table 29. Global Recombinant Human Coagulation Factor IX Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Recombinant Human Coagulation Factor IX Sales by Country/Region (2021-2026) & (K Dose)
Table 32. Global Recombinant Human Coagulation Factor IX Sales Market Share by Country/Region (2021-2026)
Table 33. Global Recombinant Human Coagulation Factor IX Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (K Dose)
Table 36. Americas Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2026)
Table 37. Americas Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 39. Americas Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (K Dose)
Table 40. APAC Recombinant Human Coagulation Factor IX Sales by Region (2021-2026) & (K Dose)
Table 41. APAC Recombinant Human Coagulation Factor IX Sales Market Share by Region (2021-2026)
Table 42. APAC Recombinant Human Coagulation Factor IX Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 44. APAC Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (K Dose)
Table 45. Europe Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (K Dose)
Table 46. Europe Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 48. Europe Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (K Dose)
Table 49. Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (K Dose)
Table 50. Middle East & Africa Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (K Dose)
Table 52. Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (K Dose)
Table 53. Key Market Drivers & Growth Opportunities of Recombinant Human Coagulation Factor IX
Table 54. Key Market Challenges & Risks of Recombinant Human Coagulation Factor IX
Table 55. Key Industry Trends of Recombinant Human Coagulation Factor IX
Table 56. Recombinant Human Coagulation Factor IX Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Recombinant Human Coagulation Factor IX Distributors List
Table 59. Recombinant Human Coagulation Factor IX Customer List
Table 60. Global Recombinant Human Coagulation Factor IX Sales Forecast by Region (2027-2032) & (K Dose)
Table 61. Global Recombinant Human Coagulation Factor IX Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Recombinant Human Coagulation Factor IX Sales Forecast by Country (2027-2032) & (K Dose)
Table 63. Americas Recombinant Human Coagulation Factor IX Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Recombinant Human Coagulation Factor IX Sales Forecast by Region (2027-2032) & (K Dose)
Table 65. APAC Recombinant Human Coagulation Factor IX Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Recombinant Human Coagulation Factor IX Sales Forecast by Country (2027-2032) & (K Dose)
Table 67. Europe Recombinant Human Coagulation Factor IX Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Forecast by Country (2027-2032) & (K Dose)
Table 69. Middle East & Africa Recombinant Human Coagulation Factor IX Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Recombinant Human Coagulation Factor IX Sales Forecast by Type (2027-2032) & (K Dose)
Table 71. Global Recombinant Human Coagulation Factor IX Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Recombinant Human Coagulation Factor IX Sales Forecast by Application (2027-2032) & (K Dose)
Table 73. Global Recombinant Human Coagulation Factor IX Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Grifols Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 75. Grifols Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 76. Grifols Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 77. Grifols Main Business
Table 78. Grifols Latest Developments
Table 79. Biogen Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 80. Biogen Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 81. Biogen Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 82. Biogen Main Business
Table 83. Biogen Latest Developments
Table 84. Octapharma Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 85. Octapharma Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 86. Octapharma Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 87. Octapharma Main Business
Table 88. Octapharma Latest Developments
Table 89. Baxter Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 90. Baxter Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 91. Baxter Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Baxter Main Business
Table 93. Baxter Latest Developments
Table 94. Cusabio Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 95. Cusabio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 96. Cusabio Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Cusabio Main Business
Table 98. Cusabio Latest Developments
Table 99. Sanofi Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 100. Sanofi Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 101. Sanofi Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Sanofi Main Business
Table 103. Sanofi Latest Developments
Table 104. Cayman Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 105. Cayman Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 106. Cayman Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Cayman Main Business
Table 108. Cayman Latest Developments
Table 109. NovoPro Bioscience Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 110. NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 111. NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. NovoPro Bioscience Main Business
Table 113. NovoPro Bioscience Latest Developments
Table 114. Sino Biological Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 115. Sino Biological Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 116. Sino Biological Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Sino Biological Main Business
Table 118. Sino Biological Latest Developments
Table 119. Bio-Techne Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 120. Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 121. Bio-Techne Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Bio-Techne Main Business
Table 123. Bio-Techne Latest Developments
Table 124. IDELVION Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 125. IDELVION Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 126. IDELVION Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. IDELVION Main Business
Table 128. IDELVION Latest Developments
Table 129. Hualan Bio Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 130. Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 131. Hualan Bio Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Hualan Bio Main Business
Table 133. Hualan Bio Latest Developments
Table 134. Shuyang Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 135. Shuyang Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 136. Shuyang Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Shuyang Main Business
Table 138. Shuyang Latest Developments
Table 139. ChinaBiologic Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 140. ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 141. ChinaBiologic Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. ChinaBiologic Main Business
Table 143. ChinaBiologic Latest Developments
Table 144. Diagbio Basic Information, Recombinant Human Coagulation Factor IX Manufacturing Base, Sales Area and Its Competitors
Table 145. Diagbio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
Table 146. Diagbio Recombinant Human Coagulation Factor IX Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Diagbio Main Business
Table 148. Diagbio Latest Developments
LIST OF FIGURES
Figure 1. Picture of Recombinant Human Coagulation Factor IX
Figure 2. Recombinant Human Coagulation Factor IX Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human Coagulation Factor IX Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Recombinant Human Coagulation Factor IX Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Recombinant Human Coagulation Factor IX Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Recombinant Human Coagulation Factor IX Sales Market Share by Country/Region (2025)
Figure 10. Recombinant Human Coagulation Factor IX Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 250 IU/Bottle
Figure 12. Product Picture of 500 IU/Bottle
Figure 13. Product Picture of 1000 IU/Bottle
Figure 14. Product Picture of 2000 IU/Bottle
Figure 15. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type in 2026
Figure 16. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2026)
Figure 17. Recombinant Human Coagulation Factor IX Consumed in Adult Patients
Figure 18. Global Recombinant Human Coagulation Factor IX Market: Adult Patients (2021-2026) & (K Dose)
Figure 19. Recombinant Human Coagulation Factor IX Consumed in Child Patients
Figure 20. Global Recombinant Human Coagulation Factor IX Market: Child Patients (2021-2026) & (K Dose)
Figure 21. Global Recombinant Human Coagulation Factor IX Sale Market Share by Application (2025)
Figure 22. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application in 2026
Figure 23. Recombinant Human Coagulation Factor IX Sales by Company in 2026 (K Dose)
Figure 24. Global Recombinant Human Coagulation Factor IX Sales Market Share by Company in 2026
Figure 25. Recombinant Human Coagulation Factor IX Revenue by Company in 2026 ($ millions)
Figure 26. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Company in 2026
Figure 27. Global Recombinant Human Coagulation Factor IX Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Recombinant Human Coagulation Factor IX Sales 2021-2026 (K Dose)
Figure 30. Americas Recombinant Human Coagulation Factor IX Revenue 2021-2026 ($ millions)
Figure 31. APAC Recombinant Human Coagulation Factor IX Sales 2021-2026 (K Dose)
Figure 32. APAC Recombinant Human Coagulation Factor IX Revenue 2021-2026 ($ millions)
Figure 33. Europe Recombinant Human Coagulation Factor IX Sales 2021-2026 (K Dose)
Figure 34. Europe Recombinant Human Coagulation Factor IX Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Recombinant Human Coagulation Factor IX Sales 2021-2026 (K Dose)
Figure 36. Middle East & Africa Recombinant Human Coagulation Factor IX Revenue 2021-2026 ($ millions)
Figure 37. Americas Recombinant Human Coagulation Factor IX Sales Market Share by Country in 2026
Figure 38. Americas Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2026)
Figure 39. Americas Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Figure 40. Americas Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026)
Figure 41. United States Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Recombinant Human Coagulation Factor IX Sales Market Share by Region in 2026
Figure 46. APAC Recombinant Human Coagulation Factor IX Revenue Market Share by Region (2021-2026)
Figure 47. APAC Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Figure 48. APAC Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026)
Figure 49. China Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 53. India Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Recombinant Human Coagulation Factor IX Sales Market Share by Country in 2026
Figure 57. Europe Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2026)
Figure 58. Europe Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Figure 59. Europe Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026)
Figure 60. Germany Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 61. France Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026)
Figure 68. Egypt Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Recombinant Human Coagulation Factor IX in 2026
Figure 74. Manufacturing Process Analysis of Recombinant Human Coagulation Factor IX
Figure 75. Industry Chain Structure of Recombinant Human Coagulation Factor IX
Figure 76. Channels of Distribution
Figure 77. Global Recombinant Human Coagulation Factor IX Sales Market Forecast by Region (2027-2032)
Figure 78. Global Recombinant Human Coagulation Factor IX Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Recombinant Human Coagulation Factor IX Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Recombinant Human Coagulation Factor IX Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Recombinant Human Coagulation Factor IX Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Recombinant Human Coagulation Factor IX Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Recombinant Human Coagulation Factor IX
Figure 2. Recombinant Human Coagulation Factor IX Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human Coagulation Factor IX Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Recombinant Human Coagulation Factor IX Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Recombinant Human Coagulation Factor IX Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Recombinant Human Coagulation Factor IX Sales Market Share by Country/Region (2025)
Figure 10. Recombinant Human Coagulation Factor IX Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 250 IU/Bottle
Figure 12. Product Picture of 500 IU/Bottle
Figure 13. Product Picture of 1000 IU/Bottle
Figure 14. Product Picture of 2000 IU/Bottle
Figure 15. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type in 2026
Figure 16. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2026)
Figure 17. Recombinant Human Coagulation Factor IX Consumed in Adult Patients
Figure 18. Global Recombinant Human Coagulation Factor IX Market: Adult Patients (2021-2026) & (K Dose)
Figure 19. Recombinant Human Coagulation Factor IX Consumed in Child Patients
Figure 20. Global Recombinant Human Coagulation Factor IX Market: Child Patients (2021-2026) & (K Dose)
Figure 21. Global Recombinant Human Coagulation Factor IX Sale Market Share by Application (2025)
Figure 22. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application in 2026
Figure 23. Recombinant Human Coagulation Factor IX Sales by Company in 2026 (K Dose)
Figure 24. Global Recombinant Human Coagulation Factor IX Sales Market Share by Company in 2026
Figure 25. Recombinant Human Coagulation Factor IX Revenue by Company in 2026 ($ millions)
Figure 26. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Company in 2026
Figure 27. Global Recombinant Human Coagulation Factor IX Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Recombinant Human Coagulation Factor IX Sales 2021-2026 (K Dose)
Figure 30. Americas Recombinant Human Coagulation Factor IX Revenue 2021-2026 ($ millions)
Figure 31. APAC Recombinant Human Coagulation Factor IX Sales 2021-2026 (K Dose)
Figure 32. APAC Recombinant Human Coagulation Factor IX Revenue 2021-2026 ($ millions)
Figure 33. Europe Recombinant Human Coagulation Factor IX Sales 2021-2026 (K Dose)
Figure 34. Europe Recombinant Human Coagulation Factor IX Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Recombinant Human Coagulation Factor IX Sales 2021-2026 (K Dose)
Figure 36. Middle East & Africa Recombinant Human Coagulation Factor IX Revenue 2021-2026 ($ millions)
Figure 37. Americas Recombinant Human Coagulation Factor IX Sales Market Share by Country in 2026
Figure 38. Americas Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2026)
Figure 39. Americas Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Figure 40. Americas Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026)
Figure 41. United States Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Recombinant Human Coagulation Factor IX Sales Market Share by Region in 2026
Figure 46. APAC Recombinant Human Coagulation Factor IX Revenue Market Share by Region (2021-2026)
Figure 47. APAC Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Figure 48. APAC Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026)
Figure 49. China Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 53. India Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Recombinant Human Coagulation Factor IX Sales Market Share by Country in 2026
Figure 57. Europe Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2026)
Figure 58. Europe Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Figure 59. Europe Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026)
Figure 60. Germany Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 61. France Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026)
Figure 68. Egypt Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Recombinant Human Coagulation Factor IX Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Recombinant Human Coagulation Factor IX in 2026
Figure 74. Manufacturing Process Analysis of Recombinant Human Coagulation Factor IX
Figure 75. Industry Chain Structure of Recombinant Human Coagulation Factor IX
Figure 76. Channels of Distribution
Figure 77. Global Recombinant Human Coagulation Factor IX Sales Market Forecast by Region (2027-2032)
Figure 78. Global Recombinant Human Coagulation Factor IX Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Recombinant Human Coagulation Factor IX Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Recombinant Human Coagulation Factor IX Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Recombinant Human Coagulation Factor IX Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Recombinant Human Coagulation Factor IX Revenue Market Share Forecast by Application (2027-2032)